Treatment Patterns and Outcomes in IgAN: An Artificial Intelligence (AI)-Enabled Analysis of 480 Patients at a Large Community Practice (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0491; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Novel agents: budesonide, sparsentan, atrasentan, iptacopan. With sparsentan, atrasentan, and iptacopan recently appearing in the data, this cohort is well-positioned to track the evolving IgAN landscape. Results Per Therapy Median values shown for initial eGFR, UPCR, UACR %/yr is normalized by years of follow up"
Clinical • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology
|
|
Sanjay Hariharan; Vish Srivastava; Terry L. Behrend; Jai Radhakrishnan
|